Avidity Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of...

from PR Newswire: https://ift.tt/2B3V9dy